Key Takeaway: Helus Pharma has appointed Michael Halstead as its new Chief Executive Officer. Halstead, a former President of Intra-Cellular Therapies, Inc., is recognized for his role in scaling the company, which was later acquired by Johnson & Johnson. His extensive experience in guiding pharmaceutical firms through late-stage clinical development is expected to enhance Helus Pharma's strategic direction.
Price reaction · baseline $7.82 (2026-07-31 close) · hit pre-market · clean, no other HELP news in the window
day 0 close · peak
+3.1%
Market Sentiment Analysis
POSITIVE FACTORS
Michael Halstead has extensive experience in the pharmaceutical industry.
He played a key role in the growth of Intra-Cellular Therapies.
His leadership is expected to benefit Helus Pharma significantly.
Full Press Release Details
Former President of Intra-Cellular Therapies, Inc. was instrumental in building and scaling the company, which was subsequently acquired by Johnson & Johnson Experienced executive with a proven track record of guiding pharmaceutical companies through late-stage clinical development and
Frequently Asked Questions
Who is the new CEO of Helus Pharma?
Michael Halstead has been appointed as the new CEO of Helus Pharma.
What was Michael Halstead's previous role?
He was the President of Intra-Cellular Therapies, Inc.
What is Halstead known for in his career?
He is recognized for scaling Intra-Cellular Therapies and guiding firms through late-stage development.